Metabolic activity of primary tumour on PET/CT has a relationship with survival in stages I‐III small‐cell lung carcinoma. (26th March 2020)

• Record Type: Journal Article
• Authors: Özdemir, Özer; Batum, Özgür; Ermin, Sinem; Aksel, Nimet; Kömürcüoğlu, Berna; Mertoğlu, Aydan; Deniz, Sami; Balcı, Günseli; Koparal, Hakan; Özbilek, Engin; Yılmaz, Ufuk
• Is Part Of: Clinical respiratory journal. Volume 14:Number 8(2020)
• Page Start: 695
• Page End: 702
• Publication Date: 2020-03-26
• Subjects: PET -- prognosis -- small cell lung cancer -- survival -- SUVmax; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13186
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Introduction: There is limited evidence about the prognostic value of FDG‐PET/CT metrics in small cell lung cancer (SCLC) patients staged with TNM staging system. Objectives: The aim of this study is to examine the prognostic value of pretreatment FDG‐SUVmax in patients with SCLC staged with 8th TNM staging system. Methods: A total of 344 (292 male) SCLC patients with pretreatment FDG‐ PET/CT were included. One hundred fifty‐three of cases were stages I‐III, 191 were stage IV. SUVmax values were obtained for primary tumour, lymph nodes and metastases. Univariate and multivariate analysis were performed to determine the effect of pretreatment SUVmax, with cut‐off value of median, on progression‐free and overall survival (PFS and OS). Results: Median OS and PFS for patients with stages I‐III were 16.50 and 11.00 months, respectively. Median OS and PFS for patients with stage IV were 10.00 and 7.00 months, respectively. SUVmax of the primary tumour (PT), lymph nodes or metastasis were not associated with OS and PFS on univariate analysis. On multivariate analysis, SUVmax ‐PT with cut‐off value of 11.60 was found to be an independent prognostic factor for OS in patients with stages I‐III (HR;1.88, 95% CI:1.15‐3.08, P = .012). But the SUVmax ‐PT (HR; 1.60, 95% CI: 0.99‐2.60; P = .057) for PFS was found to be a prognostic factor with marginal significance. SUVmax were not significantly associated with OS and PFS in patients with stage IV disease. Conclusion: Pretreatment SUVmax ‐PT (median cut‐off 11.6) may have a prognostic value of OS and PFS in patients with TNM staged I‐III SCLC.